Therapeutic Exploratory (Phase II)

3,454 trials 1,368 recruiting

Filter these 3,454 trials by condition, country, sponsor and more.

Open in Search →

A Phase IIb, Randomized, Observer-Blind study to Describe the Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different… Ended

2023-504301-37-00 Meningitis, Meningococcal 2022-03-03
PCL-2 - PRIMARY PLASMA CELL LEUKEMIA: A PROSPECTIVE PHASE II STUDY INCORPORATING DARATUMUMAB TO CHEMOTHERAPY AND STEM CELL TRANSPLANTATION (… Ended

2024-515037-15-00 PRIMARY PLASMA CELL LEUKEMIA: A PROSPECTIVE PHASE II ST 2022-03-02
Study aimed at evaluating the efficacy of the combination of the two drugs, Venetoclax and Azacitidine, on the treatment of patients sufferi… Ended

2023-510432-36-00 Acute Myeloid Leukemia with NPM1 mutation 2022-03-01
Clinical trial conducted to evaluate the effectiveness of a combination of drugs called venetoclax and rituximab adapted to the state of min… Ended

2024-518494-34-00 Chronic lymphocytic leukemia 2022-02-24
TRUST : BINTRAFUSP ALFA AND DOXORUBICIN HYDROCHLORIDE IN TREATING PATIENTS WITH ADVANCED SARCOMA Ended

2023-509497-30-00 Adult patients with locally advanced/unresectable and/o 2022-02-21
Assessment of tolerance and effectiveness of total body irradiation and cladribine before allogeneic hematopoietic cell transplantation in p… Ended

2024-517477-24-00 Acute myeloid leukemia, myelodysplastic syndromes 2022-02-17
Efficacy, safety and pharmacokinetics of rilzabrutinib in patients with warm autoimmune hemolytic anemia Ended

2023-509441-13-00 Warm autoimmune hemolytic anemia 2022-01-31
A research study to find out if the study treatment alpelisib (BYL719) is safe for a long period of time for who has confirmed diagnosis of … Ended

2023-508522-95-00 PIK3CA-Related Overgrowth Spectrum (PROS) 2022-01-27
A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis Ended

2022-502619-13-00 Relapsing Multiple Sclerosis 2022-01-25
Long-term follow-up study to evaluate durability of treatment response in previous bepirovirsen study participants (B-Sure). Ended

2023-506867-33-01 Chronic Hepatitis B 2022-01-25
PERCEPTION Ended

2023-508155-40-00 recurrent platin sensitive low-grade serous ovarian-, f 2022-01-25
A Phase II, single-arm trial of Atezolizumab/Platinum/Etoposide for the treatment of advanced large-cell neuroendocrine cancer of the lung (… Ended

2024-515902-15-00 Male and female adult patients with locally advanced or 2022-01-18
ShorTrip study - Phase II study of Short-course radiotherapy followed by consolidation chemotherapy with the Triplet FOLFOXIRI as total neoa… Ended

2024-513297-21-00 Locally advanced rectal cancer 2022-01-14
ANRS HB07 IP-Cure-B proof of concept (PoC) clinical trial. Educating the liver immune environment through TLR8 stimulation followed by NUC d… Ended

2024-515739-32-00 HBV 2022-01-10
A Study to Evaluate the Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Profiles of CGT9486 in subjects with Advanced Systemic Mastocy… Ended

2024-511407-42-00 Advanced Systemic Mastocytosis 2022-01-10
Prospective, randomized, neoadjuvant phase II study with combination immuno-oncology in primary clear cell renal cell cancer at risk for rec… Ended

2024-515514-40-00 Resectable intermediate to high-risk clear cell RCC (ac 2022-01-05
VERLEN - Phase II, Open-Label Study evaluating efficacy of Lenalidomide and Tafasitamab combination associated to Rituximab in frontline Dif… Ended

2023-507286-25-00 Diffuse Large B-Cell Lymphoma 2021-12-23
A Phase 2 Study of Tarlatamab in Patients with Small Cell Lung Cancer (SCLC). Ended

2024-511837-37-00 Relapsed/Refractory Small Cell Lung Cancer 2021-12-21
Cladribine therapy in Myasthenia Ended

2024-517083-32-00 Myasthenia gravis 2021-12-17
Radiation during Osimertinib Treatment: a Safety and Efficacy Cohort Study (ROSE) Ended

2022-503028-29-01 Patients with stage IV EGFR-mutation positive NSCLC tar 2021-12-14
Multi-drug treatment for breast cancer patients with brain metastases Ended

2024-510703-11-00 HER2+ metastatic breast cancer with isolated brain prog 2021-12-13
Acalabrutinib and rituximab in elderly patients with untreated mantle cell lymphoma (ALTAMIRA) Ended

2023-509864-96-00 Mantle Cell Lymphoma (MCL) 2021-12-07
Study aimed at evaluating the efficacy of a combination treatment (decitabine and venetoclax) in patients with Acute Myeliode Leukemia who a… Ended

2023-510241-16-00 Acute Myeloid Leukemia secondary to myeloproliferative 2021-12-03
Study to evaluate the effects of CLR 131 in patients with B-Cell malignancies (CLOVER-1) and expansion study to evaluate the effects of CLR … Ended

2023-508671-37-00 Waldenstrom Macroglobulinemia 2021-12-02